Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First US kidney cancer vaccine trial underway at Columbia

31.01.2005


Study of a Completely New Way of Trying to Treat Cancer in the Future by the Use of Vaccination Injections



The first U.S. kidney cancer vaccine trial is now underway at Columbia University Medical Center and NewYork-Presbyterian Hospital/Columbia. While the potential for vaccines to treat solid tumors has been recognized for more than a decade, this trial is pioneering the use of tumor immunotherapy – boosting the body’s natural immune system – as a way to fight cancer.

“Vaccines are an exciting prospect in cancer treatment and this trial is an example of our program’s dedication to bringing the latest advances in tumor vaccines and immunotherapy to patients with cancer,” said Howard L. Kaufman, M.D., associate professor of surgery and pathology at Columbia University Medical Center and director, Tumor Immunotherapy Program at NewYork-Presbyterian/Columbia. “We expect that combining IL-2 with Trovax will double the treatment response rate for our kidney cancer patients, offering new hope for these patients.”


Vaccines, usually associated with the prevention of infectious diseases, e.g., measles, help the body’s immune system recognize and kill foreign invading organisms. Recent research has provided evidence that vaccines may also be useful for preventing or treating cancer. Tumor vaccines contain a specific protein of the tumor cell that stimulates an immune response.

In the study, patients with stage IV renal cell carcinoma are given regular doses of an investigational kidney cancer vaccine, called Trovax, in conjunction with Interleukin-2 (IL-2). High-dose IL-2 is currently the only approved treatment for kidney cancer, and Columbia University Medical Center and New York-Presbyterian Hospital/Columbia are the only site in New York to offer IL-2. Kidney cancer is one of the few cancers for which chemotherapies are not effective treatments.

A small protein (cytokine) naturally produced by the cells of the immune system, IL-2 stimulates T-cells, which are activated in an immune response system and create tumor killing cells. The response rate (i.e., rate of tumor shrinkage) of IL-2 given alone is typically 17-25 percent. While IL-2 stimulates all T-cells, the Trovax Vaccine helps IL-2 selectively target only cancer cells, reducing side effects by not targeting and unnecessarily killing normal cells. Trovax has shown promise in similar trials conducted in Europe in colon cancer.

About Trovax

Trovax belongs to a class of medicines called a vaccine. Trovax consists of a virus that has been changed so that it is no longer infectious and carries a gene for a protein called 5T4. This protein is carried by many kidney cancer calls. When the virus is injected, it makes the protein, and the body’s immune system is then able to recognize this protein and kill the cells that have it (i.e. the cancer cells).

About the Trial

The Trovax vaccine with IL-2 trial is being conducted by a team of physicians, scientists, nurses, pharmacists, and social workers with expertise in the use of immunotherapy in patients with cancer.

The trial aims to enroll 25 patients in total. To date, two patients have enrolled. Patients need to meet certain medical requirements to join the clinical trial. An interested patient or medical oncologist may contact us to learn about eligibility requirements. Participation is voluntary and patients may withdraw at any time.

For more information regarding participation in one of our trials, please contact Gail DeRaffele, RN, Clinical Coordinator at 212.342.0232 or gd2023@columbia.edu.

The Tumor Immunotherapy Program at NewYork-Presbyterian/Columbia, unique in the Metropolitan New York area, includes doctors and nurses with specialized training in biologic therapy and vaccines who are actively conducting clinical studies of tumor vaccines. The program also includes scientists working in research laboratories within Columbia University to translate clinical learnings into new vaccines and therapies.

Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, medical education, and health care. The medical center trains future leaders in health care and includes the dedicated work of many physicians, scientists, nurses, dentists, and other health professionals at the College of Physicians & Surgeons, the School of Dental & Oral Surgery, the School of Nursing, the Mailman School of Public Health, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. With a strong history of some of the most important advances and discoveries in health care, its researchers are leading the development of novel therapies and advances to address a wide range of health conditions.

New York-Presbyterian Hospital is the largest not-for-profit, non-sectarian hospital in the country. It provides state-of-the art inpatient, ambulatory and preventive care in all areas of medicine at five major centers: New York-Presbyterian hospital/Columbia University Medical Center, New York-Presbyterian Hospital/Weill Cornell Medical Center, Children’s Hospital of New York-Presbyterian, the Allen Pavilion, and the Westchester Division. It consistently ranks as one of the top hospitals in the country in U.S. News & World Report’s guide to “America’s Best Hospitals.” The New York-Presbyterian Healthcare System – an affiliation of acute-care and community hospitals, long-term care facilities, ambulatory sites, and specialty institutes –serves one in four patients in the New York metropolitan area.

Elizabeth Streich | EurekAlert!
Further information:
http://www.columbia.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>